argenx SE Stock

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles 11:35:00 2024-06-14 EDT 5-day change 1st Jan Change
360.9 EUR +0.64% Intraday chart for argenx SE +1.78% +5.07%

Financials

Sales 2024 * 1.71B 1.83B 2.52B Sales 2025 * 2.32B 2.48B 3.41B Capitalization 21.45B 22.96B 31.53B
Net income 2024 * -146M -156M -215M Net income 2025 * 169M 181M 248M EV / Sales 2024 * 11.1 x
Net cash position 2024 * 2.43B 2.6B 3.57B Net cash position 2025 * 2.55B 2.73B 3.75B EV / Sales 2025 * 8.15 x
P/E ratio 2024 *
-152 x
P/E ratio 2025 *
170 x
Employees 1,148
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.88%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.64%
1 week+1.78%
Current month+5.93%
1 month+4.61%
3 months+5.28%
6 months-14.86%
Current year+5.07%
More quotes
1 week
342.80
Extreme 342.8
366.10
1 month
328.10
Extreme 328.1
366.10
Current year
322.50
Extreme 322.5
381.10
1 year
271.00
Extreme 271
494.10
3 years
224.10
Extreme 224.1
494.10
5 years
93.05
Extreme 93.05
494.10
10 years
6.23
Extreme 6.23
494.10
More quotes
Managers TitleAgeSince
Founder 52 07-12-31
Director of Finance/CFO 54 21-05-31
Chief Tech/Sci/R&D Officer - 14-12-31
Members of the board TitleAgeSince
Director/Board Member 71 17-04-25
Director/Board Member 74 15-05-12
Director/Board Member 63 16-04-27
More insiders
Date Price Change Volume
24-06-14 360.9 +0.64% 42,355
24-06-13 358.6 +2.37% 47,402
24-06-12 350.3 -0.40% 42,459
24-06-11 351.7 +0.31% 35,223
24-06-10 350.6 -1.13% 35,374

Real-time Euronext Bruxelles, June 14, 2024 at 11:35 am

More quotes
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
360.9 EUR
Average target price
436.6 EUR
Spread / Average Target
+20.97%
Consensus